A number of therapies from a range of drug classes are available to address the symptoms of narcolepsy, which include excessive daytime sleepiness and cataplexy. Despite many available pharmacological treatments, a large proportion of patients have inadequate control of their narcolepsy symptoms. Given that the narcolepsy treatment is highly individualized and complex, it is essential to understand the use of current therapies in the nuanced narcolepsy treatment algorithm ahead of anticipated product launches. Our Treatment Algorithms research leverages national patient-level claims data to explore the use of key therapies in narcolepsy, such as modafinil, armodafinil, and Xyrem, in both newly diagnosed and recently treated patients.
Geographies: United States
Real-world data: Longitudinal patient-level claims data analysis
Key drugs covered: Armodafinil, atomoxetine, modafinil, Sunosi, Vyvanse, Wakix, Xyrem
Key companies covered: Eli Lilly, Harmony Biosciences, Jazz Pharmaceuticals, Takeda, Teva
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.